Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, filed terms Monday morning. The NY based company plans to offer 5.5 million shares at a range of $11 to $13. Banc of America is the lead manager on the deal.
Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, filed terms Monday morning. The NY based company plans to offer 5.5 million shares at a range of $11 to $13. Banc of America is the lead manager on the deal.